US 11,931,424 B2
Combination MCL-1 inhibitors with anti-body drug conjugates
Thomas F. Kenney, Seattle, WA (US); Clinton K. Matson, Redmond, WA (US); and Chandrasekar Venkataramani, San Carlos, CA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Jun. 9, 2022, as Appl. No. 17/836,480.
Claims priority of provisional application 63/322,509, filed on Mar. 22, 2022.
Claims priority of provisional application 63/209,667, filed on Jun. 11, 2021.
Prior Publication US 2022/0409736 A1, Dec. 29, 2022
Int. Cl. A61K 47/68 (2017.01); A61K 31/519 (2006.01); A61K 31/553 (2006.01); A61P 11/00 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01)
CPC A61K 47/6851 (2017.08) [A61K 31/519 (2013.01); A61K 31/553 (2013.01); A61K 47/6803 (2017.08); A61P 11/00 (2018.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01)] 15 Claims
 
1. A method of treating a Trop-2 expressing cancer comprising:
administering to a human patient in need a therapeutically effective amount of an antibody-drug conjugate, and a therapeutically effective amount of an MCL-1 inhibitor;
wherein the antibody-drug conjugate comprises an anti-Trop-2 antibody and an anticancer agent that is SN-38; and
wherein the MCL-1 inhibitor is compound A:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.